Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.8%

Neg 0% Neu 89.8% Pos 0%

Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $55 price target.

Comments

No comments yet. Be the first!